- Home
- ONFO vs ENSC Comparison
ONFO vs ENSC Comparison
Compare ONFO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- ENSC
- Stock Information
- Founded
- ONFO 2018
- ENSC 2003
- Country
- ONFO United States
- ENSC United States
- Employees
- ONFO N/A
- ENSC N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- ENSC Health Care
- Exchange
- ONFO Nasdaq
- ENSC Nasdaq
- Market Cap
- ONFO 5.8M
- ENSC 4.9M
- IPO Year
- ONFO 2022
- ENSC N/A
- Fundamental
- Price
- ONFO $0.96
- ENSC $2.22
- Analyst Decision
- ONFO
- ENSC
- Analyst Count
- ONFO 0
- ENSC 0
- Target Price
- ONFO N/A
- ENSC N/A
- AVG Volume (30 Days)
- ONFO 114.4K
- ENSC 230.3K
- Earning Date
- ONFO 08-13-2025
- ENSC 08-13-2025
- Dividend Yield
- ONFO N/A
- ENSC N/A
- EPS Growth
- ONFO N/A
- ENSC N/A
- EPS
- ONFO N/A
- ENSC N/A
- Revenue
- ONFO $9,087,118.00
- ENSC $6,224,081.00
- Revenue This Year
- ONFO N/A
- ENSC N/A
- Revenue Next Year
- ONFO N/A
- ENSC $1,381.48
- P/E Ratio
- ONFO N/A
- ENSC N/A
- Revenue Growth
- ONFO 65.97
- ENSC 256.35
- 52 Week Low
- ONFO $0.61
- ENSC $1.62
- 52 Week High
- ONFO $1.88
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- ONFO 45.29
- ENSC 49.53
- Support Level
- ONFO $0.87
- ENSC $2.02
- Resistance Level
- ONFO $1.48
- ENSC $2.30
- Average True Range (ATR)
- ONFO 0.11
- ENSC 0.14
- MACD
- ONFO -0.00
- ENSC 0.02
- Stochastic Oscillator
- ONFO 13.11
- ENSC 43.40
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.